HERTHENA-Lung02: Phase III trial of patritumab deruxtecan in EGFR-mutated NSCLC post EGFR TKI
Вставка
- Опубліковано 27 вер 2024
- This video article presents the phase III HERTHENA-Lung02 study protocol, investigating the use of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.
Subscribe: / @videojournalofbiomedi...
Visit The Video Journal of Biomedicine: www.biomedicin...
Follow us on X: / vjofbiomedicine
LinkedIn: / video-journal-of-biome...
Facebook: / videojournalbiomedicine
#cancer #egfr #nsclc #lungcancer